-
Pfizer Files Flurry of Lawsuits Over Migraine Medication Patent
28 May 2024 22:34 GMT
Pfizer recently filed at least seven lawsuits in federal court seeking to enjoin multiple multinational pharmaceutical companies from selling a generic version of its medication, Nurtec, which is used to prevent and treat migraines.
These suits were …
-
Pfizer Stock: Chart Indicates a Long-Term Bottom , But Is the Dividend Safe?
27 May 2024 07:19 GMT
… returned currently to shareholders. Pfizer still sports an investment- … .
Morningstar did note that Pfizer is on track for … a portfolio construction standpoint, Pfizer is one of those stocks … terms of cost savings and patented drug product. That acquisition …
-
How Much Will Pfizer Pay Out in Dividends This Year?
26 May 2024 13:20 GMT
… benefit from patent-protected market exclusivity.
With patents on drugs … that many patients can't live without, Pfizer … , investors can expect Pfizer to distribute significantly more … raises bought millions of Pfizer shares during the …
-
Adrenal crisis Market Forecast 2034: FDA Approvals, Clinical Trials, Pipeline, Epidemiology & Companies by DelveInsight
28 May 2024 14:37 GMT
… Pharmaceutical, Sandoz International GmbH, Pfizer Inc, Bristol-Myers Squibb, Merck … collaborations, acquisitions, mergers, licensing patent details, and other information for … Pharmaceutical, Sandoz International GmbH, Pfizer Inc, Bristol-Myers Squibb, Merck …
-
Biosimilars Market Projected to Surge to USD 108.8 Billion by 2031, Growing at a CAGR of 17.7% from 2024 to 2031
28 May 2024 14:20 GMT
… by Increasing Adoption and Patent Expiries of Blockbuster Biologics … the expiration of key patents for blockbuster biologic drugs … ; Co. Inc.
- Pfizer Inc.
- reliance life sciences … frameworks.
Key Takeaways
• Patent expiries of blockbuster biologic drugs …
-
Hemophilia B Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
27 May 2024 12:15 GMT
… (Genzyme)/Alnylam Pharmaceuticals, Pfizer/ Spark Therapeutics, Novo … therapies, FITUSIRAN (Sanofi), Marstacimab (Pfizer), SerpinPC (Centessa Pharmaceuticals and … collaborations, acquisitions, mergers, licensing patent details, and other information …
-
Hemophilia A Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
27 May 2024 12:05 GMT
… Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx … , acquisitions, mergers, licensing patent details, and other information … Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx …
-
Neurovascular Adverse Effects of Sars-Cov-2 Vaccination
29 May 2024 19:00 GMT
… vaccines, like BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 ( … embolism following vaccination with Pfizer-BioNTech’s BNT162b2, … of Oxford-AstraZeneca and Pfizer-BioNTech vaccines observed slightly … M, Noc M. Patent foramen ovale-associated stroke and …
-
Merck Stock: Still Discounted To Graham P/E
29 May 2024 19:45 GMT
… Keytruda franchise has also surpassed Pfizer’s Comirnaty COVID-19 franchise … the fact that it’s patent-protected until 2028. We also …
-
Neurocrine, a regular name on Wall Street’s M&A lists, elevates BD chief to succeed founder and CEO
29 May 2024 21:25 GMT
… below its IPO price after Pfizer walked out on a partnership … the lead inventor on the patent to the valbenazine molecule that …